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were used to compare outcomes across satisfaction groups. Results: Only 64 (4.08%) 
were satisfied with their treatment, and 1504 (95.92%) not satisfied. A positive relation-
ship was observed between satisfaction and HRQoL, with the most satisfied group 
recording a 31.62% higher EQ-5D score (mean 0.75 vs. 0.57, p< 0.01) relative to the next 
most-satisfied group. A negative relationship was observed between satisfaction and 
pain, with the most satisfied patient group scoring 30.89% lower pain scores (mean 
3.40 vs. 4.91, p< 0.01). ConClusions: Most neuropathic pain patients are not satis-
fied with their current pain therapy. This analysis suggests a negative relationship 
between treatment satisfaction and reported pain severity as well as a clear positive 
relationship between treatment satisfaction and health related quality of life. The 
results highlight the need for a more targeted treatment of neuropathic pain patients.
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objeCtives: According to the Pain in Europe Study, about one in five EU adults 
have chronic pain. Back pain / lower back pain is among the most commonly cited 
location of pain.1 Additionally, research has suggested that pain has a negative 
impact on sufferer mental health, employment, sleep and personal relationships.2 
This analysis profiles and compares adults experiencing back pain to adults with-
out pain across 5EU. Methods: Results were taken from the 2011 5EU National 
Health and Wellness Survey, a nationally representative, self-administered survey. 
Respondents were adults age 18 and over from France, Germany, Italy, Spain and 
UK. This analysis focuses on adults diagnosed with back pain or experienced pain 
as a result of back problem in the past month- (“patients with back pain”). Quality 
of life was measured using the SF12v2 scale. Activity impairment was measured 
using the Work Productivity and Activity Impairment scale. Results: Out of the 
total sample of n= 57,512, ~10% (n= 5,984) have back pain. Relative to adults without 
pain, back pain sufferers are older on average (48.9 vs. 46.3), more likely to be women 
(57% vs. 48%), and obese (27% vs. 16%). Their overall mental and physical quality of 
life scores are significantly lower (43.2 vs. 47.9, p < 0.001 and 40.3 vs. 50.9, p < 0.001). 
In addition, back pain sufferers are exhibited more work impairment (absenteeism 
and presenteeism) and activity impairment, and utilized health care resources to a 
greater extent than non-sufferers (i.e., greater physician visits, hospitalization, and 
ER). All these results are notably higher among back pain patients treated with a pre-
scription. ConClusions: Considering the prevalence of back pain among adults, 
the level of work impairment and quality of life limitations impacts a substantial 
portion of adults in the 5EU population. Improvements in treatment of back pain 
are needed to reduce this burden.
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objeCtives: Reversal of the residual effect of rocuronium or vecuronium by neostig-
mine may be slow and associated with side-effects. Sugammadex, a selective relaxant 
binding agent, encapsulates rocuronium to provide for a rapid reversal of residual 
neuromuscular blockade. Also, postoperative residual neuromuscular block can 
reduce delay of awakening, recovery, and dissatisfaction of patient. The aim of this 
study is to evaluate the willingness-to-pay (WTP) of sugammadex for effectiveness 
and safety using a contingent valuation method. Methods: A total of 505 adult 
general population and 60 experts (anesthesiologist and surgeon) participated in 
a face-to-face survey. The respondents were surveyed separately each scenario of 
moderate and deep blocks for surgery. The scenario was designed to provide informa-
tion concerning reversal time on neuromuscular block, adverse reaction of PRNB, and 
quality of surgery or recovery. The out-of-pocket WTP for sugammadex was utilized 
open answer. Results: In general population, WTP values for sugammadex were 
81,768 Korean won (KRW) in moderate block and 128,622 KRW in deep block. The same 
sample answered 89,017 KRW and 141,536 KRW for WTP for their family members 
in moderate block and deep block, respectively. Experts were estimated the WTP of 
99,417 KRW in moderate block and 153,250 KRW in deep block. For patients, experts 
suggested that 82,517 KRW and 132,517 KRW were appropriate WTP. The WTP was sta-
tistically significantly higher in the general population who had been taken operation 
and older than their counterparts. ConClusions: The WTP for sugammadex was 
ranged the 81,768 to 99,417 KRW in moderate block, and the 128,622 to 153,250 KRW 
in deep block. The WTP of general population for their family members was higher 
than the WTP for their own, and the expert’s WTP was higher than their patients.
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objeCtives: To assess rheumatologist perception towards biosimilars and the 
likelihood of use of biosimilars to manage RA patients in the EU, Brazil, Japan and 
China. Methods: A multi-country cross-sectional survey was conducted in top-5 
EU countries (UK/Germany/Spain/France/Italy), Brazil, Japan and China in April/
May 2013 using an online physician panel in the respective geographies; rheu-
matologists were randomly selected for survey participation to be geographically 
representative in select countries/regions. Surveys assessed the rheumatologist 
perceptions of biosimilars in terms of factors that would prevent them from using 
RS6:43.7;28.5,60.0)+(NPRS7: 46.3;31.1,61.5)+(NPRS8: 58.5;42.6,74.4)+(NPRS9:2.0;44.2,
79.8)+(NPRS10:72.2;54.7,89.7). The estimated marginal mean WPAI-NP-AI increased 
linearly from 10.1% at NPRS 0 to 84.8% at NPRS 10. Predicted WPAI-NP-AI was highly 
correlated with observed values (R-squared= 0.889); mean absolute error (predicted-
observed) was 9.6 (sd 6.9). ConClusions: In people with chronic NP, increasing 
pain severity was associated with a linear increase in impairment of regular daily 
activities other than paid work. Interventions that reduce pain are likely to improve 
functioning.
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objeCtives: Bariatric surgery is the best long-term treatment for morbid obesity 
with clinical improves, like reductions in blood pressure, glucose and lipids levels. 
However postoperative complications and psychosocial issues may impact qual-
ity of life (QoL). This study aims to assess health-related quality of life (HRQoL) in 
Brazilian obese patients submitted to bariatric surgery. Methods: A systematic 
review was conducted by April 2013 through Cochrane Collaboration, Medline, 
EMBASE, and Lilacs databases. Studies that described QoL in Brazilian obese 
patients were included in this review. Bariatric Analysis and Reporting Outcome 
System (BAROS), Moorehead-Ardelt quality of life questionnaire II (M-A-QoLQII), 
Abbreviated WHOQoL questionnaire and Short Form-6D (SF-6D) were used to evalu-
ate the behavior of patients who underwent bariatric surgery in relation to QoL 
domains. Results: Seven studies met eligibility criteria. In all studies, individuals 
presented body mass index (BMI) ≥ 40kg/m2 or ≥ 35 kg/m2 associated with comor-
bidities. Patients reported their self-esteem (SE), physical activity (PA), social rela-
tions (SR), disposition to work (DW) and sexual activity (SA), after bariatric surgery. 
According to the M-A-QoLQII, three studies showed HRQoL improvement in 28.9%, 
39.5%, 28.4%, 30% and 25.6% of patients for SE, PA, SR, DW and SA, respectively. 
And 68.9%, 50.6%, 53.1%, 52.2%, 45.6% of patients guaranteed greatly improved 
regarding those parameters, respectively. After weight loss, bariatric surgery was 
effective to improve QoL in PA domain. Besides, when compared to patients submit-
ted to medical treatment, patients who underwent surgical procedure presented 
an improvement of 93% in HRQoL, contrasting with 65.4% of the medical cohort 
(p< 0.001). Only one study measured QoL before and after bariatric surgery: SF-36 
domains and M-A-QoLQII showed that post-surgery results were invariably better 
than pre-surgery ones (p< 0.001 for all domains). ConClusions: The present review 
demonstrated the potential QoL improvements in Brazilian patients after bariatric 
surgery, in addition to clinical benefits.
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objeCtives: To analyze the cost of therapy for patients with chronic myeloid 
leukemia (CML) and their quality of life. Methods: It is retrospective as regard 
to cost and prospective as regard to quality of life analysis. Five university hospi-
tals in four major cities treating all 320 CML-patients are included for the period 
2011-2012. Information is collected from the patients’ records about the health 
care resources used as medicines for CML, additional therapy, hospitalizations 
and physicians visits. The assessment of health related quality of life is con-
ducted with validated for the country SF-36 questionnaire. Results: A total of 
164 (51.2%) men and 156 (48.75%) women, average age 53.96±15.41 were observed. 
The average CML pharmacotherapy monthly cost is 5976.4 BGN, the average total 
pharmacotherapy cost for additional diseases is 566.27 BGN and the average addi-
tional costs for physicians’ visits and hospitalization is equal to 1504.69 BGN. The 
most expensive CML therapy is with Dasatinib 7771.20 BGN and the cheapest is 
Imatinib therapy equal to 5245.15 BGN. The most common additional diseases are 
cardiovascular (68%), followed by endocrine (29%). There is significant correlation 
between overall assessment for quality of life and average total additional costs 
– the higher assessment for QoL, the lower costs for hospitalization and visits. 
With the significantly highest score is the scale Bodily pain, followed by Physical 
functioning, and the lowest are Vitality, energy or fatigue and Role limitation. In 
most of patients on Imatinib (77.9%) are recorded good hematological responses 
and 66.7% are with major molecular response. ConClusions: CML is a disease 
consuming significant health care resources especially for major pharmacother-
apy with TKIs. Infrequent physicians’ visits and rarer hospitalizations generate 
higher assessment of quality of life.
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objeCtives: Neuropathic pain (NP) is a chronic progressive disease which is hard 
to control. This analysis investigates patients’ satisfaction with pain therapy and its 
relationship with pain severity and health related quality of life (HRQoL). Methods: 
Data were drawn from the 2012 Adelphi NP Disease Specific Programme, a cross-
sectional study involving 413 primary care physicians and specialists across Europe. 
Physicians provided detailed records for 3956 NP patients, of which 1568 patients 
voluntarily completed EQ-5D and Brief Pain Inventory questionnaires. HRQoL was 
measured via the EQ-5D, satisfaction via a three-option question answered by the 
patient, and pain via the Brief Pain Inventory (BPI) interference score. Boxplot analyses 
